An In-silico analysis of anticancer property of doxorubicin on polysaccharide encapsulation
Material type:
TextSubject(s): Dissertation note: Master of Science in Computational Science 2013-2015 EXT " Division of Cancer Research, Regional Cancer Centre, Thiruvananthapuram " Summary: The objective of present project is to modify existing chemotherapeutic agents, to minimize side effects and enhance drug delivery to effectively and precisely in cancer cells. Doxorubicin (Dox) is a commonly used chemotherapeutic agent. It is also known by its trade name, Adriamycin and is used against different types of cancer. Doxorubicin can cause side effects such as myelosuppression, cardiomyopathies and drastic decrease in the number of blood cells in bone marrow etc. Usage of Dox is associated with serious heart problems also. Other side effects associated with Dox include vomiting, nausea, stomach problems, low blood count, loss of appetite, eye problem and hair loss. In order to avoid the side effects of Dox, polysaccharide encapsulated Dox has been tested against various cancer pathways using in-silico methods. A model compound of complex of doxorubicin drug with Galactoxyloglucan (polysaccharide) tested against proteins such as 3QX3 (DNA topoisomerase 2-beta; TOP2B_HUMAN), 3CS9 (Human Abl kinase) and 3QRJ (Protein tyrosine kinase). Computations show that encapsulation enhances the activity of drug.
| Item type | Current library | Call number | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|
Project Reports
|
Kerala University of Digital Sciences, Innovation and Technology Knowledge Centre | Not for loan | R-649 |
Master of Science in Computational Science 2013-2015 EXT T.K Manoj Kumar T.T Sreelekha (Assistant Professor) " Division of Cancer Research, Regional Cancer Centre, Thiruvananthapuram "
The objective of present project is to modify existing chemotherapeutic agents, to minimize side effects and enhance drug delivery to effectively and precisely in cancer cells. Doxorubicin (Dox) is a commonly used chemotherapeutic agent. It is also known by its trade name, Adriamycin and is used against different types of cancer. Doxorubicin can cause side effects such as myelosuppression, cardiomyopathies and drastic decrease in the number of blood cells in bone marrow etc. Usage of Dox is associated with serious heart problems also. Other side effects associated with Dox include vomiting, nausea, stomach problems, low blood count, loss of appetite, eye problem and hair loss. In order to avoid the side effects of Dox, polysaccharide encapsulated Dox has been tested against various cancer pathways using in-silico methods. A model compound of complex of doxorubicin drug with Galactoxyloglucan (polysaccharide) tested against proteins such as 3QX3 (DNA topoisomerase 2-beta; TOP2B_HUMAN), 3CS9 (Human Abl kinase) and 3QRJ (Protein tyrosine kinase). Computations show that encapsulation enhances the activity of drug.
There are no comments on this title.